Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo.
Noninvasive Quantitative PET Imaging in Humans of the Pancreatic Beta-Cell Mass Biomarkers VMAT2 and Dopamine D2/D3 Receptors In Vivo.
复制标题
人体胰腺 β 细胞群生物标志物 VMAT2 和多巴胺 D2/D3 受体的无创定量 PET 成像。
DOI：
10.1007/978-1-0716-2807-2_4
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Cline,GaryW
中科院分区：
文献类型：
--
作者：
Bini,Jason;Carson,RichardE;Cline,GaryW
β细胞的非侵入性定量成像可以提供有关细胞转运蛋白、受体和信号蛋白变化的信息，这些变化可能影响功能和/或质量损失，这两者都有助于1型或2型糖尿病（T1 D/T2 D）患者胰岛素分泌和葡萄糖调节的丧失。我们已经开发并优化了两种正电子发射断层扫描（PET）放射性配体，[18 F]FP-（+）-DTBZ和[11 C]（+）-PHNO的使用，分别靶向β细胞VMAT 2和多巴胺（D2/D3）受体。在这里，我们描述了我们的优化方法，这两种示踪剂的定量PET成像的β细胞生物标志物在体内的临床应用。我们还简要讨论了我们以前的结果及其影响和价值，将PET放射性配体的使用扩展到β细胞质量定量成像的原始目标之外，以提供对β细胞质量和/或功能丧失的生物学的洞察，并评估治疗剂预防或恢复功能性β细胞质量的疗效。
Noninvasive quantitative imaging of beta-cells can provide information on changes in cellular transporters, receptors, and signaling proteins that may affect function and/or loss of mass, both of which contribute to the loss of insulin secretion and glucose regulation of patients with type 1 or type 2 diabetes (T1D/T2D). We have developed and optimized the use of two positron emission tomography (PET) radioligands, [18F]FP-(+)-DTBZ and [11C](+)-PHNO, targeting beta-cell VMAT2 and dopamine (D2/D3) receptors, respectively. Here we describe our optimized methodology for the clinical use of these two tracers for quantitative PET imaging of beta-cell biomarkers in vivo. We also briefly discuss our previous results and their implications and value towards extending the use of PET radioligand beyond the original goal of quantitative imaging of beta-cell mass to the potential to provide insight into the biology of beta-cell loss of mass and/or function and to evaluate the efficacy of therapeutics to prevent or restore functional beta-cell mass.